Converging Cell Therapy with Biomaterials

Cellular Transplantation

Volumn , Issue , 2007, Pages 591-609

  Ali, Omar A ^a   Mooney, David J ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882483766     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369415-7/50032-6     Document Type: Chapter

References (180)

1. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer Disease in the U.S. Population Prevalence Estimates Using the 2000 Census. Archives of Neurology August 2003, 60(8):1119-1122.
2. The American Burn Association Estimate of total burn incidence extracted from the National Health Interview Survey (NHIS) 2005, U.S. Department of Health and Human Service: Centers for Disease Control and Prevention, National Center for Health Statistics, Chicago, IL.
3. American Diabetes Association Estimates of the total number of persons with diabetes and the prevalence of diabetes in 2005 were derived using 1999-2002 National Health and Nutrition Exami Survey (NHANES), 1999-2003 National Health Interview Survey (NHIS), 2003 IHS data, and 2005 resident population estimates 2005, Alexandria, VA.
4. Thorn T., Haase N., Rosamond W., Howard V.J., Rumsfeld J., et al. Heart disease and stroke statistics- 2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee 2006, Circulation 83-151.
5. The National Institutes of Health Autoimmune Research Plan 2002, NIH Publication No. 03-5140, December. N.I.O. Health (Ed.).
6. U.S.Department of Health Human Services The 2004 Surgeon General's Report on Bone Health and Osteoporosi: What It Means to You 2004, U.S. Department of Health and Human Services, Office of the Surgeon General.
7. National Birth Defects Prevention Network (NBDPN) . State Birth Defects Surveillance Program Directory. Birth Defects Research Part A 2005, 73:700-757.
8. National Parkinson Foundation The National Parkinson Foundation Annual Report 2005, Miami, Fl.
9. The National Spinal Cord Injury Statistical Center at the University of Alabama at Birmingham Spinal Cord Injurie: Facts and Statistics 2005, Bethesda, MD. N.S.C.I.A.(.N.S.C.I.A.). The (Ed.).
10. Cancer Statistics Branch of the National Cancer Institute (NCI) SEER Cancer Statistics Review SEER Incidence and US Mortality Trends, 1992-2002 2002, N.C. Institute (Ed.).
11. Alsberg E., Anderson K.W., Albeiruti A., Franceschi R.T., Mooney D.J. Cell-interactive alginate hydrogels for bone tissue engineering. J Dent Res 2001, 80:2025-2029.
12. Alsberg E., Kong H.J., Hirano Y., Smith M.K., Albeiruti A., Mooney D.J. Regulating bone formation via controlled scaffold degradation. J Dent Res 2003, 82:903-908.
13. Anderson J.M. Biological responses to materials. Annu Rev Mater Res 2001, 31:81-110.
14. Anderson J.M., Defife K., McNally A., Collier T., Jenney C.Monocyte macrophage and foreign body giant cell interactions with molecularly engineered surfaces. J Mater Sci Mater Med 1999, 10:579-588.
15. Aplin A.E., Howe A.K., Juliano R.L. Cell adhesion molecules signal transduction and cell growth. Curr Opin Cell Biol 1999, 11:737-744.
16. Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999, 190:995-1004.
17. Avellino A.M., Hart D., Dailey A.T., MacKinnon M., Ellegala D., Kliot M. Differential macrophage responses in the peripheral and central nervous system during wallerian degeneration of axons. Exp Neurol 1995, 136:183-198.
18. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
19. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
20. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003, 9:1202-1208.
21. Bell E. Tissue engineering in perspective. Principles of Tissue Engineering 2000, xxxv-xli. Academic Press, San Diego, CA. 2nd ed. R.P. Lanza, R. Langer, J. Vacanti (Eds.).
22. Bendeck M.P. Macrophage matrix metalloproteinase-9 regulates angiogenesis in ischemic muscle. Circ Res 2004, 94:138-139.
23. Bianco P., Robey P.G. Stem cells in tissue engineering. Nature 2001, 414:118-121.
24. Bingle L., Brown N.J., Lewis C.E. The role of tumourassociated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 2002, 196:254-265.
25. Björklund A. Cell therapy for Parkinson's disease: Problems prospects. Novartis Found Symp 2005, 265:174-186.
26. Björklund A. Cell therapy for Parkinson's disease: Problems prospects. Novartis Found Symp 2005, 265:187. discussion.
27. Björklund A. Cell therapy for Parkinson's disease: Problems prospects. Novartis Found Symp 2005, 265:204-211.
28. Bloch J., Fine E.G., Bouche N., Zurn A.D., Aebischer P. Nerve growth factor-and neurotrophin-3-releasing guidance channels promote regeneration of the transected rat dorsal root. Exp Neurol 2001, 172:425-432.
29. Boontheekul T., Mooney D.J. Protein-based signaling systems in tissue engineering. Curr Opin Biotechnol 2003, 14:559-565.
30. Boyce S.T., Kagan R.J., Meyer N.A., Yakuboff K.P., Warden G.D. The 1999 clinical research award. Cultured skin substitutes combined with integra artificial skin to replace native skin autograft and allograft for the closu excised full-thickness burns. J Burn Care Rehabil 1999, 20:453-461.
31. Boyce S.T., Kagan R.J., Yakuboff K.P., Meyer N.A., Rieman M.T., Greenhalgh D.G., Warden G.D. Cultured skin substitutes reduce donor skin harvesting for closure of excised full-thickness burns. Ann Surg 2002, 235:269-279.
32. Bronte V., Chappell D.B., Apolloni E., Cabrelle A., Wang M., Hwu P., Restifo N.P. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigenpresenting cell matu. J Immunol 1999, 162:5728-5737.
33. Bruck W. The role of macrophages in wallerian degeneration. Brain Pathol 1997, 7:741-752.
34. Caroleo M.C., Costa N., Bracci-Laudiero L., Aloe L. Human monocyte/macrophages activate by exposure to LPS overexpress NGF and NGF receptors. J Neuroimmunol 2001, 113:193-201.
35. Caux C., Dezutter-Dambuyant C., Schmitt D., Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992, 360:258-261.
36. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., Falo L.D. Peptide-pulsed dendritic cells induce antigenspecific CTL-mediated protective tumor immunity. J Exp Med 1996, 183:283-287.
37. Chaikof E.L. Engineering and material considerations in islet cell transplantation. Annu Rev Biomed Eng 1999, 1:103-127.
38. Chen R.R., Mooney D.J. Polymeric growth factor delivery strategies for tissue engineering. Pharm Res 2003, 20:1103-1112.
39. Chinn J.A. Biomaterial: Protein-surface interactions. The Biomedical Engineering Handbook 1995, 1597-1608. CRC Press, Boca Raton, Florida. J.D. Bronzino (Ed.).
40. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P.C., Pan Y.C., Olander J.V., Connolly D.T., Stern D. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell monocyte procoagulant activity and promotes monocyte migration. J Exp Med 1990, 172:1535-1545.
41. Correale P., Campoccia G., Tsang K.Y., Micheli L., Cusi M.G., Sabatino M., Bruni G., Sestini S., Petrioli R., Pozzessere D., Marsili S., Fanetti G., Giorgi G., Francini G.Recruitment of dendritic cells, enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Eur J Cancer 2001, 37:892-902.
42. Crowther M., Brown N.J., Bishop E.T., Lewis C.E. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 2001, 70:478-490.
43. Cruikshank W.W., Kornfeld H., Center D. M Interleukin-16. J Leukoc Biol 2000, 67:757-766.
44. Curiel T.J., Curiel D.T. Tumor immunotherapy: Inching toward the finish line. J Clin Invest 2002, 109:311-312.
45. Dallal R.M., Lotze M.T. The dendritic cell and human cancer vaccines. Curr Opin Immunol 2000, 12:583-588.
46. Diegelmann R.F., Evans M.C. Wound healing: An overview of acute fibrotic and delayed healing. Front Biosci 2004, 9:283-289.
47. Diez-Roux G., Argilla M., Makarenkova H., Ko K., Lang R.A. Macrophages kill capillary cells in G1 phase of the cell cycle during programmed vascular regression. Development 1999, 126:2141-2147.
48. Dipietro L.A., Reintjes M.G., Low Q.E., Levi B., Gamelli R.L. Modulation of macrophage recruitment into wounds by monocyte chemoattractant protein-1. Wound Repair Regen 2001, 9:28-33.
49. Dittmer U., Olbrich A.R. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr Opin Microbiol 2003, 6:472-477.
50. Donnelly J.J., Wahren B., Liu M.A. DNA vaccine: Progress and challenges. J Immunol 2005, 175:633-639.
51. Dorotka R., Windberger U., Macfelda K., Bindreiter U., Toma C., Nehrer S. Repair of articular cartilage defects treated by microfracture and a three-dimensional collagen matrix. Biomaterials 2005, 26:3617-3629.
52. Dove A. Cell-based therapies go live. Nat Biotechnol 2002, 20:339-343.
53. Elgert K.D., Alleva D.G., Mullins D.W. Tumor-induced immune dysfunction: The macrophage connection. J Leukoc Biol 1998, 64:275-290.
54. Evans G.R., Brandt K., Katz S., Chauvin P., Otto L., Bogle M., Wang B., Meszlenyi R.K., Lu L., Mikos A.G., Patrick C.W. Bioactive poly (L-lactic acid) conduits seeded with Schwann cells for peripheral nerve regeneration. Biomaterials 2002, 23:841-848.
55. Fang J., Zhu Y.Y., Smiley E., Bonadio J., Rouleau J.P., Goldstein S.A., McCauley L.K., Davidson B.L., Roessler B.J. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci USA 1996, 93:5753-5758.
56. Faraasen S., Voros J., Csucs G., Textor M., Merkle H.P., Walter E. Ligand-specific targeting of microspheres to phagocytes by surface modification with poly (L-lysine) -grafted poly (ethylene glycol) conjugate. Pharm Res 2003, 20:237-246.
57. Fondevila C., Shen X.D., Moore C., Busuttil R.W., Coito A.J. Cyclic RGD peptides with high affinity for alpha5beta1 integrin protect genetically fat Zucker rat livers from cold ischemia/reperfusion injury. Transplant Proc 2005, 37:1679-1681.
58. Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000, 18:245-273.
59. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53:31-47.
60. Franklin R.J., Barnett S.C. Do olfactory glia have advantages over Schwann cells for CNS repair? J Neurosci Res 1997, 50:665-672.
61. Franzen R., Schoenen J., Leprince P., Joosten E., Moonen G., Martin D. Effects of macrophage transplantation in the injured adult rat spinal cord: A combined immunocytochemical and biochemical study. J Neurosci Res 1998, 51:316-327.
62. Fraser R.B., MacAulay M.A., Wright J.R., Sun A.M., Rowden G. Migration of macrophage-like cells within encapsulated islets of Langerhans maintained in tissue culture. Cell Transplant 1995, 4:529-534.
63. Freedman S.B., Isner J.M. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002, 136:54-71.
64. Goede V., Brogelli L., Ziche M., Augustin H.G. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999, 82:765-770.
65. Goldsby R., Kindt T., Osborne B., Kuby J. Immunology 2003, W. H. Freeman and Company, New York.
66. Gombotz W.R., Pettit D.K. Biodegradable polymers for protein and peptide drug delivery. Bioconjug Chem 1995, 6:332-351.
67. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
68. Gordon S., Fraser I., Nath D., Hughes D., Clarke S. Macrophages in tissues and in vitro. Curr Opin Immunol 1992, 4:25-32.
69. Greisler H.P., Gosselin C., Ren D., Kang S.S., Kim D.U. Biointeractive polymers and tissue engineered blood vessels. Biomaterials 1996, 17:329-336.
70. Griffith L.G. Emerging design principles in biomaterials and scaffolds for tissue engineering. Ann NYAcad Sci 2002, 961:83-95.
71. Guan J.L., Hynes R.O. Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell 1990, 60:53-61.
72. Guest J.D., Rao A., Olson L., Bunge M.B., Bunge R.P. The ability of human Schwann cell grafts to promote regeneration in the transected nude rat spinal cord. Exp Neurol 1997, 148:502-522.
73. Hackstein H., Thomson A.W. Dendritic cell: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004, 4:24-34.
74. Hagege A.A., Carrion C., Menasche P., Vilquin J.T., Duboc D., Marolleau J.P., Desnos M., Bruneval P. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet 2003, 361:491-492.
75. Hauben E., Gothilf A., Cohen A., Butovsky O., Nevo U., Smirnov I., Yoles E., Akselrod S., Schwartz M. Vaccination with dendritic cells pulsed with peptides of myelin basic protein promotes functional recovery from spinal cord injury. J Neurosci 2003, 23:8808-8819.
76. Healy K.E., Rezania A., Stile R.A. Designing biomaterials to direct biological responses. Ann NY Acad Sci 1999, 875:24-35.
77. Herbelin A., Gombert J.M., Lepault F., Bach J.F., Chatenoud L. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol 1998, 161:2620-2628.
78. Hill H.C., Conway T.F., Sabel M.S., Jong Y.S., Mathiowitz E., Bankert R.B., Egilmez N.K. Cancer immunotherapy with interleukin 12 and granulocytemacrophage colony-stimulating factor-encapsulated microsphere: Coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002, 62:7254-7263.
79. Hirano Y., Mooney D.J. Peptide and protein presenting materials for tissue engineering. Advanced Materials 2004, 16:17-25.
80. Hobson M.I., Green C.J., Terenghi G. VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy. J Anat 2000, 197:591-605. (Pt 4).
81. Holder W.D., Gruber H.E., Roland W.D., Moore A.L., Culberson C.R., Loebsack A.B., Burg K.J.L., Mooney D.J. Increased vascularization and heterogeneity of vascular structures occurring in polyglycolide matrices containing aortic endothelial cells implanted in the ra. Tissue Engineering 1997, 3:149.
82. Horbett T.A. Proteins Structure, properties, and adsorption to surfaces. Biomaterials Science 1996, Academic Press. 133-140.
83. Huang Y.C., Riddle K., Rice K.G., Mooney D.J. Long-term in vivo gene expression via delivery of PEI-DNA condensates from porous polymer scaffolds. Hum Gene Ther 2005, 16:609-617.
84. Hubbell J.A., Massia S.P., Desai N.P., Drumheller P.D. Endothelial cell-selective materials for tissue engineering in the vascular graft via a new receptor. Biotechnology (NY) 1991, 9:568-572.
85. Hubert P., Evrard B., Maillard C., Franzen-Detrooz E., Delattre L., Foidart J.M., Noel A., Boniver J., Delvenne P. Delivery of granulocyte-macrophage colonystimulating factor in bioadhesive hydrogel stimulates migration of dendritic cells in models of human papillomavirusa (pre) neoplastic epithelial lesions. Antimicrob Agents Chemother 2004, 48:4342-4348.
86. Humes H.D., Szczypka M.S. Advances in cell therapy for renal failure. Transpl Immunol 2004, 12:219-227.
87. Jenne L., Arrighi J.F., Jonuleit H., Saurat J.H., Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res 2000, 60:4446-4452.
88. Kao W.J., Hubbell J.A., Anderson J.M. Protein-mediated macrophage adhesion and activation on biomaterial:Amodel for modulating cell behavior. J Mater Sci Mater Med 1999, 10:601-605.
89. Kao W.J., Liu Y. Intracellular signaling involved in macrophage adhesion and FBGC formation as mediated by ligand-substrate interaction. J Biomed Mater Res 2002, 62:478-487.
90. Kao W.J., Liu Y., Gundloori R., Li J., Lee D., Einerson N., Burmania J., Stevens K. Engineering endogenous inflammatory cells as delivery vehicles. J Control Release 2002, 78:219-233.
91. Kaplan J.M., Armentano D., Sparer T.E., Wynn S.G., Peterson P.A., Wadsworth S.C., Couture K.K., Pennington S.E., St George J.A., Gooding L.R., Smith A.E. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum Gene Ther 1997, 8:45-56.
92. Kodelja V., Muller C., Tenorio S., Schebesch C., Orfanos C.E., Goerdt S. Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 1997, 197:478-493. Nov.
93. Kong H.J., Liu J., Riddle K., Matsumoto T., Leach K., Mooney D.J. Non-viral gene delivery regulated by stiffness of cell adhesion substrates. Nat Mater 2005, 4:460-464.
94. Kong H.J., Polte T.R., Alsberg E., Mooney D.J. FRET measurements of cell-traction forces and nano-scale clustering of adhesion ligands varied by substrate stiffness. Proc Natl Acad Sci USA 2005, 102:4300-4305.
95. Kumamoto T., Huang E.K., Paek H.J., Morita A., Matsue H., Valentini R.F., Takashima A. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat Biotechnol 2002, 20:64-69.
96. Kuo P.Y., Saltzman W.M. Novel systems for controlled delivery of macromolecules. Crit Rev Eukaryot Gene Expr 1996, 6:59-73.
97. Labow R.S., Erfle D.J., Santerre J.P. Neutrophilmediated degradation of segmented polyurethanes. Biomaterials 1995, 16:51-59.
98. Langer R. Drug delivery and targeting. Nature 1998, 392:5-10.
99. Lee K.Y., Peters M.C., Anderson K.W., Mooney D.J. Controlled growth factor release from synthetic extracellular matrices. Nature 2000, 408:998-1000.
100. Lei Y., Haider H., Shujia J., Sim E.S. Therapeutic angiogenesis. Devising new strategies based on past experiences. Basic Res Cardiol 2004, 99:121-132.
101. Lepault F., Gagnerault M.C. Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 2000, 164:240-247.
102. Levy M.Y., Barron L.G., Meyer K.B., Szoka F.C. Characterization of plasmid DNA transfer into mouse skeletal muscle: Evaluation of uptake mechanism expression and secretion of gene products into blood. Gene Ther 1996, 3:201-211.
103. Lohr J., Knoechel B., Jiang S., Sharpe A.H., Abbas A.K. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 2003, 4:664-669.
104. Mann B.K., Schmedlen R.H., West J.L. Tethered-TGF-beta increases extracellular matrix production of vascular smooth muscle cells. Biomaterials 2001, 22:439-444.
105. Massia S.P., Hubbell J.A. Human endothelial cell interactions with surface-coupled adhesion peptides on a nonadhesive glass substrate and two polymeric biomaterials. J Biomed Mater Res 1991, 25:223-242. Feb.
106. Massia S.P., Hubbell J.A. Vascular endothelial cell adhesion and spreading promoted by the peptide REDV of the IIICS region of plasma fibronectin is mediated by integrin alpha 4 beta 1. J Biol Chem 1992, 267:14019-14026.
107. Mayordomo J.I., Zorina T., Storkus W.J., Zitvogel L., Celluzzi C., Falo L.D., Melief C.J., Ildstad S.T., Kast W.M., Deleo A.B., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995, 1:1297-1302.
108. Mazzoni A., Bronte V., Visintin A., Spitzer J.H., Apolloni E., Serafini P., Zanovello P., Segal D.M. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002, 168:689-695.
109. McElvaney N.G. Is gene therapy in cystic fibrosis a realistic expectation?. Curr Opin Pulm Med 1996, 2:466-471.
110. Meadows M. Bone marrow transplants come of age. New hope for deadly diseases. FDA Consum 2000, 34:22-27.
111. Mellman I., Steinman R.M. Dendritic cell: Specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
112. Mikos A.G., McIntire L.V., Anderson J.M., Babensee J.E. Host response to tissue engineered devices. Adv Drug Deliv Rev 1998, 33:111-139.
113. Moldovan N.I. Role of monocytes and macrophages in adult angiogenesi: A light at the tunnel's end. J Hematother Stem Cell Res 2002, 11:179-194.
114. Moldovan N.I., Goldschmidt-Clermont P.J., Parker-Thornburg J., Shapiro S.D., Kolattukudy P.E. Contribution of monocytes/macrophages to compensatory neovascularization: The drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res 2000, 87:378-384.
115. Mosser D.M. The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212.
116. Muldashev E.R., Muslimov S.A., Musina L.A., Nigmatullin R.T., Lebedeva A.I., Shangina O.R., Khasanov R.A. The role of macrophages in the tissues regeneration stimulated by the biomaterials. Cell Tissue Bank 2005, 6:99-107.
117. Murdoch C., Lewis C.E. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer 2005, 117:701-708.
118. Okada N., Masunaga Y., Okada Y., Mizuguchi H., Iiyama S., Mori N., Sasaki A., Nakagawa S., Mayumi T., Hayakawa T., Fujita T., Yamamoto A. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Ther 2003, 10:1891-1902.
119. Oppenheim J.J. Cytokines: Past present and future. Int J Hematol 2001, 74:3-8.
120. Oudega M., Hagg T. Nerve growth factor promotes regeneration of sensory axons into adult rat spinal cord. Exp Neurol 1996, 140:218-229.
121. Paglia P., Chiodoni C., Rodolfo M., Colombo M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996, 183:317-322.
122. Pannier A.K., Shea L.D. Controlled release systems for DNA delivery. Mol Ther 2004, 10:19-26.
123. Park S., Healy K.E. Nanoparticulate DNA packaging using terpolymers of poly (lysine-g- (lactide-b-ethylene glycol) ). Bioconjug Chem 2003, 14:311-319.
124. Perry D. Patients' voice: The powerful sound in the stem cell debate. Science 2000, 287:1423.
125. Perry V.H., Brown M.C. Macrophages and nerve regeneration. Curr Opin Neurobiol 1992, 2:679-682.
126. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
127. Radbruch A., Thiel A. Cell therapy for autoimmune disease: Does it have a future?. Ann Rheum Dis 2004, 63(Suppl 2):ii96-ii101.
128. Read S., Malmstrom V., Powrie F. Cytotoxic T lymphocyteassociated antigen 4 plays an essential role in the function of CD25 (+) CD4 (+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295-302.
129. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001, 19:1029-1034.
130. Riddle K.W., Mooney D.J. Role of poly (lactide-coglycolide) particle size on gas-foamed scaffolds. J Biomater Sci Polym Ed 2004, 15:1561-1570.
131. Rizzi S.C., Hubbell J.A. Recombinant protein-co-PEG networks as cell-adhesive proteolytically degradable hydrogel matrixes Part I: Development and physicochemical characteristics. Biomacromolecules 2005, 6:1226-1238.
132. Robitaille R., Dusseault J., Henley N., Rosenberg L., Halle J.P. Insulin-like growth factor II allows prolonged blood glucose normalization with a reduced islet cell mass transplantation. Endocrinology 2003, 144:3037-3045.
133. Rosenberg S.A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996, 88:1635-1644.
134. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994, 86:1159-1166.
135. Russo V., Tanzarella S., Dalerba P., Rigatti D., Rovere P., Villa A., Bordignon C., Traversari C. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci USA 2000, 97:2185-2190.
136. Sakiyama S.E., Schense J.C., Hubbell J.A. Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: An example of designer matrices in tissue engineering. Faseb J 1999, 13:2214-2224.
137. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin and downregulated by tumor necrosis factor alpha. J Exp Med 1994, 179:1109-1118.
138. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., Bluestone J.A. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
139. Schense J.C., Bloch J., Aebischer P., Hubbell J.A. Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension. Nat Biotechnol 2000, 18:415-419.
140. Schmeisser A., Garlichs C.D., Zhang H., Eskafi S., Graffy C., Ludwig J., Strasser R.H., Daniel W.G. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res 2001, 49:671-680.
141. Schmidt C.E., Leach J.B. Neural tissue engineering: Strategies for repair and regeneration. Annu Rev Biomed Eng 2003, 5:293-347.
142. Schuler G., Schuler-Thurner B., Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003, 15:138-147.
143. Schwartz M., Lazarov-Spiegler O., Rapalino O., Agranov I., Velan G., Hadani M. Potential repair of rat spinal cord injuries using stimulated homologous macrophages. Neurosurgery 1999, 44:1041-1045.
144. Schwartz M., Lazarov-Spiegler O., Rapalino O., Agranov I., Velan G., Hadani M. Potential repair of rat spinal cord injuries using stimulated homologous macrophages. Neurosurgery 1999, 44:1045-1046. discussion.
145. Schwartz M., Yoles E. Macrophages and dendritic cells treatment of spinal cord injury: From the bench to the clinic. Acta Neurochir Suppl 2005, 93:147-150.
146. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colonystimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004, 64:6337-6343.
147. Shea L.D., Smiley E., Bonadio J., Mooney D.J. DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol 1999, 17:551-554.
148. Sheridan M.H., Shea L.D., Peters M.C., Mooney D.J. Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. J Control Release 2000, 64:91-102.
149. Sica A., Saccani A., Mantovani A. Tumor-associated macrophage:Amolecular perspective. Int Immunopharmacol 2002, 2:1045-1054.
150. Silva E.A., Mooney D.J. Synthetic extracellular matrices for tissue engineering and regeneration. Curr Top Dev Biol 2004, 64:181-205.
151. Singh B., Read S., Asseman C., Malmstrom V., Mottet C., Stephens L.A., Stepankova R., Tlaskalova H., Powrie F. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001, 182:190-200.
152. Sittinger M., Bujia J., Rotter N., Reitzel D., Minuth W.W., Burmester G.R. Tissue engineering and autologous transplant formation: Practical approaches with resorbable biomaterials and new cell culture techniques. Biomaterials 1996, 17:237-242.
153. Song E., Ouyang N., Horbelt M., Antus B., Wang M., Exton M.S. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol 2000, 204:19-28.
154. Stout R.D., Jiang C., Matta B., Tietzel I., Watkins S.K., Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005, 175:342-349.
155. Stout R.D., Suttles J. Functional plasticity of macrophage: Reversible adaptation to changing microenvironments. J Leukoc Biol 2004, 76:509-513.
156. Stout R.D., Suttles J. T cell signaling of macrophage activation Cell contact-dependent cytokine signals. 1995, Austin TX R.G. Landes Company, Springer-Verlag.
157. Stout R.D., Suttles J. T cell signaling of macrophage function in inflammatory disease. Front Biosci 1997, 2:197-206.
158. Suh W., Kim K.L., Kim J.M., Shin I.S., Lee Y.S., Lee J.Y., Jang H.S., Lee J.S., Byun J., Choi J.H., Jeon E.S., Kim D.K. Transplantation of endothelial progenitor cells accelerates dermal wound healing with increased recruitment of monocytes/macrophages and neovascularization. Stem Cells; 2005.
159. Sunderkotter C., Goebeler M., Schulze-Osthoff K., Bhardwaj R., Sorg C. Macrophage-derived angiogenesis factors. Pharmacol Ther 1991, 51:195-216.
160. Tang L., Eaton J.W. Inflammatory responses to biomaterials. Am J Clin Pathol 1995, 103:466-471.
161. Tang L., Lucas A.H., Eaton J.W. Inflammatory responses to implanted polymeric biomaterial: Role of surface-adsorbed immunoglobulin G. J Lab Clin Med 1993, 122:292-300.
162. Tang L., Ugarova T.P., Plow E.F., Eaton J.W. Molecular determinants of acute inflammatory responses to biomaterials. J Clin Invest 1996, 97:1329-1334.
163. Tarbell K.V., Yamazaki S., Olson K., Toy P., Steinman R.M. CD25+ CD4+ T cells expanded with dendritic cells presenting a single autoantigenic peptide suppress autoimmune diabetes. J Exp Med 2004, 199:1467-1477.
164. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4 (+) CD25 (+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
165. Tobias C.A., Han S.S., Shumsky J.S., Kim D., Tumolo M., Dhoot N.O., Wheatley M.A., Fischer I., Tessler A., Murray M. Alginate encapsulated BDNF-producing fibroblast grafts permit recovery of function after spinal cord injury in the absence of immune suppression. J Neurotrauma 2005, 22:138-156.
166. Tran N., Li Y., Bertrand S., Bangratz S., Carteaux J.P., Stoltz J.F., Villemot J.P. Autologous cell transplantation and cardiac tissue engineering: Potential applications in heart failure. Biorheology 2003, 40:411-415.
167. Tuszynski M.H., Gabriel K., Gage F.H., Suhr S., Meyer S., Rosetti A.Nerve growth factor delivery by gene transfer induces differential outgrowth of sensory motor and noradrenergic neurites after adult spinal cord injury. Exp Neurol 1996, 137:157-173.
168. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
169. Vander A., Sherman J., Luciano D. Human physiology: The mechanism of body function 2001, McGraw Hill.
170. Vats A., Tolley N.S., Polak J.M., Gough J.E. Scaffolds and biomaterials for tissue engineering: A review of clinical applications. Clin Otolaryngol Allied Sci 2003, 28:165-172.
171. Vejsada R., Tseng J.L., Lindsay R.M., Acheson A., Aebischer P., Kato A.C. Synergistic but transient rescue effects of BDNF and GDNF on axotomized neonatal motoneurons. Neuroscience 1998, 84:129-139.
172. Waeckerle-Mena Y., Groettrupa M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Advanced Drug Delivery Reviews 2005, 57:475-482.
173. Wagner V.E., Bryers J.D. Monocyte/macrophage interactions with base and linear-and star-like PEG-modified PEG-poly (acrylic acid) co-polymers. J Biomed Mater Res A 2003, 66:62-78.
174. Wewers M.D. Cytokines in health and disease 1992, pp 235-256, Marcel Dekker, New York.
175. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
176. Xu X.M., Guenard V., Kleitman N., Bunge M.B. Axonal regeneration into Schwann cell-seeded guidance channels grafted into transected adult rat spinal cord. J Comp Neurol 1995, 351:145-160.
177. Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., Steinman R.M. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003, 198:235-247.
178. Yu M., Finn O.J. DNA vaccines for cancer too. Cancer Immunol Immunother 1-12; 2005.
179. Zhao X., Jain S., Benjamin Larman H., Gonzalez S., Irvine D.J. Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials 2005, 26:5048-5063.
180. Ziats N.P., Miller K.M., Anderson J.M. In vitro and in vivo interactions of cells with biomaterials. Biomaterials 1988, 9:5-13.